The U.S. Food and Drug Administration is reviewing Orexigen Therapeutics’ experimental weight-loss drug Contrave, the last of three prescription diet pills up for U.S. consideration this year.

The agency will release its staff’s assessment of the drug on Friday before a public meeting on the drug December 7.

Following is a list of approved obesity drugs, others that were discontinued, and those awaiting approval.

Factbox: A short history of U.S. obesity drugs | Reuters